

July 13, 2021

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: Jane Park  
Tim Buchmiller

**Re: TScan Therapeutics, Inc.**  
**Registration Statement on Form S-1**  
**File No. 333-255491**

**Request for Acceleration of Effective Date**

**Requested Date: Thursday, July 15, 2021**

**Requested Time: 4:00 P.M. Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, TScan Therapeutics, Inc. (the “**Company**”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-255491) (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, by calling Keith Scherer at 617-648-9231.

*[Signature page follows]*

Sincerely,

TScan Therapeutics, Inc.

By: /s/ David Southwell  
Chief Executive Officer  
*Principal Executive Officer*

cc: Timothy Ehrlich, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP  
Jeffrey R. Vetter, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP  
Keith Scherer, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP